ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
<>
24/06/08
[PDF] Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Study
L Lancaster, V Cottin, M Ramaswamy, WA Wuyts… - American Journal of …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease characterized by altered lung structure and function due to excessive extracellular matrix deposition with … (1-7) Median life expectancy for untreated patients with IPF …
- 特発性肺線維症患者におけるベキソテグラスト：INTEGRIS-IPF 研究
Mechanism of Maimendong decoction in treating idiopathic pulmonary fibrosis based on network pharmacology and experimental validation.
MA Xian, YU Mingyue, Z Bowen, LI Zefeng… - Journal of Hainan Medical …, 2024
… mechanism of Maimendong decoction on idiopathic pulmonary fibrosis by utilizing network … applied to obtain target genes of idiopathic pulmonary fibrosis. Venn diagrams drawing tool … Finally, we used bleomycin to establish a pulmonary …
- ネットワーク薬理学と実験検証に基づく、特発性肺線維症の治療における麦門冬煎じ薬のメカニズム。
[HTML] Aberrant lipid metabolism in pulmonary inflammation linked to lung cancer progression; a preliminary study
D Lee, J Mun, I Choi, J Joo - Journal of Translational Medicine, 2024
… Idiopathic pulmonary fibrosis (IPF), one of the main cause of lung cancer (LC), induces dysfunction of lipid metabolism (LM) into hypoxic … of LCs, IPF through quantitative analysis of lipid metabolites. We analyzed the difference in metabolite …
- 肺の炎症における脂質代謝の異常は肺がんの進行と関連している；予備研究
[HTML] Noninvasive assessment of pulmonary hypertension: key insights to maximize chest computed tomography
L Nardone, P Minichetti, SL Sauro, C Simiele, G Agati… - Journal of Medical Imaging …, 2024
… , idiopathic pulmonary fibrosis (IPF), chronic hypersensitivity pneumonitis, pulmonary Langerhans cell histiocytosis, and sarcoidosis are the ILDs that most commonly complicate with PH [39]. Other conditions include combined pulmonary …
- 肺高血圧症の非侵襲的評価：胸部CTを最大限に活用するための重要な洞察
24/06/07
The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
M Żuber, P Dąbrowska, M Dacka - Quality in Sport, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic, rare disease characterized by continuous … Symptoms of IPF include shortness of breath, dry cough and reduced exercise tolerance, leading … In Poland, patients with IPF can benefit from …
- 特発性肺線維症の治療におけるニンテダニブとピルフェニドンの役割とIPF治療の最近の臨床試験のレビュー
[PDF] Effects of antifibrotic therapy with nintedanib or pirfenidone on mortality and other clinical endpoints in IPF: a systematic review
R Koosha - 2024
… However, worsening of idiopathic pulmonaryfibrosis was also a defined efficacy endpoint in this study, and when excluded as a serious adverse event, the percentage of patients with serious adverse events was 18.7% in the pirfenidone …
- ニンテダニブまたはピルフェニドンによる抗線維化療法がIPFの死亡率およびその他の臨床エンドポイントに及ぼす影響：系統的レビュー
Incidence and survival of Interstitial Lung Diseases in the UK in 2000-2022: real-world data from the OPCRD primary care database.
F Gonnelli, N Eleangovan, U Smith, TJ Corte, V Carter… - The ERS Congress 2024, 2024
… Methods: We extracted incident cases of hypersensitivity pneumonitis, connective tissue disease related ILD, and idiopathic pulmonaryfibrosis (IPF) for the years 2000-2022. We analysed the IPF using three-degrees levels of coding. We calculated crude …
- 2000～2022年の英国における間質性肺疾患の発生率と生存率：OPCRDプライマリケアデータベースからの実際のデータ。
Fabrication and Evaluation of Spray Dried Polymeric Nanoparticle Dry Powder for Inhalation: A Strategy to Deliver Nintedanib to Lungs
UY Nayak, V Velagacherla - 2024
… Idiopathic Pulmonary Fibrosis (IPF) stands as a challenging and debilitating lung disorder, characterized … of IPF by inhibiting multiple growth factors and pathways involved in fibrosis. By harnessing the potential of nanotechnology and surface …
- 吸入用スプレー乾燥ポリマーナノ粒子乾燥粉末の製造と評価：ニンテダニブを肺に送達する戦略
[PDF] Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date
SJ Cassady, JAN Almario, GV Ramani - Drug, Healthcare and Patient Safety, 2024
… ILD of a variety of causes, with idiopathicinterstitial pneumonia being the most common type. … the idiopathic interstitial pneumonia patients, particularly idiopathic pulmonaryfibrosis (IPF). … with idiopathic pulmonaryfibrosis independent of the …
- 肺動脈性高血圧症患者に対するトレプロスチニル吸入粉末の治療効果：これまでのエビデンス
CHARACTERIZATION AND ANALYSIS OF NINTEDANIB ESYLATE IN AQUEOUS SOLUTIONs
M McCray
… Nintedanib Esylate is an on market gel capsule oral dosage therapeutic for idiopathicpulmonary fibrosis and is classified as a BCS class II or IV drug due to its low solubility. The purpose of this study is to first understand the gel-point of this …
- 水溶液中のニンテダニブエシル酸塩の特性と分析
[HTML] Fibroblast senescence-associated extracellular matrix promotes heterogeneous lung niche
AM Howes, NC Dea, D Ghosh, K Krishna, Y Wang, Y Li… - APL Bioengineering, 2024
… Finally, we examined patient samples diagnosed with pulmonary fibrosis to further tie our results of the in vitro model to clinical outcomes… idiopathic pulmonary fibrosis(IPF), a chronic age-related pulmonary fibrotic disease, is …
- 線維芽細胞の老化に関連する細胞外マトリックスは、異質な肺ニッチを促進する
24/06/06
Promising advances in treatments for the management of idiopathic pulmonary fibrosis
C Sofia, A Comes, G Sgalla, L Richeldi - Expert Opinion on Pharmacotherapy, 2024
… Idiopathic pulmonary fibrosis (IPF) represents a chronic respiratory condition of uncertain origin … Various aspects, including location and age, influence the impact of IPF, with a notable rise … by studies involving animal models of pulmonary fibrosis …
- 特発性肺線維症の治療における有望な進歩
[HTML] Improvement in idiopathic interstitial pneumonia by adding macitentan to a patient unresponsive to nintedanib
Y Tanaka, S Kaburaki, T Tanaka, K Kamio, T Okano… - Respiratory Medicine Case …, 2024
… In patients with idiopathic pulmonaryfibrosis (IPF), an increase in endothelin levels in both serum and bronchoalveolar lavage … idiopathic pulmonary fibrosis (IPF), failed to demonstrate the efficacy of bosentan in suppressing the progression of IPF …
- ニンテダニブに反応しない患者にマシテンタンを追加することで特発性間質性肺炎が改善
[HTML] Prognostic Function and Immunologic Landscape of a Predictive Model Based on Five Senescence-Related Genes in IPF Bronchoalveolar Lavage Fluid
C Zhong, Y Lei, J Zhang, Q Zheng, Z Liu, Y Xu, S Shan… - Biomedicines, 2024
… Background: Idiopathic pulmonary fibrosis(IPF) is a type of interstitial lung disease characterized by unknown causes and a poor prognosis. Recent research indicates that age-related mechanisms, such as cellular senescence, may play a …
- IPF 気管支肺胞洗浄液中の 5 つの老化関連遺伝子に基づく予測モデルの予後機能と免疫学的展望
[PDF] A novel senolytic drug for pulmonary fibrosis: BTSA1 targets apoptosis of senescent myofibroblasts by activating BAX
M Shen, J Fu, Y Zhang, Y Chang, X Li, H Cheng, Y Qiu… - Aging Cell, 2024
… Idiopathic pulmonary fibrosis is a progressive and age- related disease that results from … attenuates pulmonary fibrosis, revealing a detrimental role of these cells in pulmonary fibrosis. … and alleviated both reversible and irreversible …
- 肺線維症に対する新しい老化細胞除去薬：BTSA1はBAXを活性化することで老化した線維芽細胞のアポトーシスを標的とする
[HTML] [68Ga] FAPI PET for Imaging and Treatment Monitoring in a Preclinical Model of Pulmonary Fibrosis: Comparison to [18F] FDG PET and CT
H Ji, X Song, X Lv, F Shao, Y Long, Y Song, W Song… - Pharmaceuticals, 2024
… Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by abnormal activation of myofibroblasts, which induces injury of lung epithelium or endothelium via excessive deposition of collagen and extracellular matrix proteins …
- [68Ga] FAPI PETによる肺線維症の前臨床モデルにおける画像診断および治療モニタリング: [18F] FDG PETおよびCTとの比較
Macrophages and Pulmonary Fibrosis: A Bibliometric and Visual Analysis of Publications from 1990 to 2023
Y Min, C Xu, W Han, Z Yin, X Pan - Frontiers in Medicine
… The role of macrophages in the symptomatic and structural progression of pulmonaryfibrosis (PF) has garnered significant scholarly … The prevailing keywords encompass pulmonary fibrosis, acute lung injury, idiopathic pulmonary …
- マクロファージと肺線維症: 1990年から2023年までの出版物の計量書誌学的および視覚的分析
Diffuse Parenchymal Lung Disease and the Inherent Limitations of a Glossary
JR Galvin, TJ Franks - Radiology, 2024
… histologic assessment, patients with idiopathic pulmonary fibrosis show a marked reduction in … the consensus conference definition of idiopathic pulmonary fibrosis, mosaic change at CT … part of the pathophysiologic abnormalities of idiopathic …
- びまん性肺実質疾患と用語集の固有の限界
24/06/05
Miniaturized Drug Discovery Assays Targeting Macrophages in Fibrotic Diseases
S Groetzner - 2024
… idiopathic pulmonary fibrosis (IPF), defective removal of apoptotic cells (efferocytosis) by macrophages was reported. Therefore, targeting macrophages and especially the modulation of their efferocytotic activity represents one strategy to diminish …
- 線維性疾患におけるマクロファージを標的とした小型創薬アッセイ
24/06/03
[HTML] Impact of emphysema on mortality in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Y Wang, R Zou, Y Yao, C Tang, J Luo, M Lin - European Journal of Inflammation, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrosing interstitial lung disease. The effects of emphysema on mortality in IPF … The term idiopathic pulmonaryfibrosis (IPF) refers to a chronic and progressive fibrosing …
- 特発性肺線維症における肺気腫の死亡率への影響：系統的レビューとメタアナリシス
[PDF] Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis (IPF): The Best Is the Enemy of the Good
S Stowasser, GP Cosgrove, E White - American Journal of Respiratory and Critical …, 2024
… FVC poses significant challenges for drug developers and the pulmonary fibrosiscommunity, as new drug candidates now must demonstrate … potential endpoints in IPF clinical trials are noble; we should all be focusing on meaningfully improving the …
- 特発性肺線維症（IPF）患者の気分、機能、生存を評価する：最善は善の敵である
[PDF] Idiopathic Pulmonary Fibrosis: A Narrative Literature Review
N Febrina, D Wijaya - Bioscientia Medicina: Journal of Biomedicine and …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a part of interstitial lung disease (ILD) with unknown causes. Interstitial lung diseases are a large … unknown causes which are referred to as idiopathic interstitial pneumonias (IIPs). Idiopathic pulmonary fibrosis …
- 特発性肺線維症：叙述的文献レビュー
Reply to Stowasser et al.: Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis (IPF): The Best Is the Enemy of the Good
G Raghu, TR Fleming, FJ Martinez - American Journal of Respiratory and Critical …, 2024
We thank the authors of the Letter in Response for their insightful contribution to our report on Meaningful Endpoints for Idiopathic pulmonary clinical trials (1). We offer one clarification relating to the importance of having proper rigor when justifying …
- Stowasser らへの返答: 特発性肺線維症 (IPF) 患者の気分、機能、生存の評価: 最善は善の敵
MicroRNA Let-7d Mediated Mesenchymal Stem Cell Exosomes Against Idiopathic Pulmonary Fibrosis Through Epithelial-Mesenchymal Transition Progress
J Liu, X Han, M Gu, Q Zhao, Q Li, X Liu - 2024
… Idiopathic interstitial pulmonary fibrosis(IPF) is a pulmonary interstitial disease with unclear origin. The clinical histopathology of IPFwhich … But, the study on the pathogenesis and treatment of IPF is still insufficient. However, stem cells' …
- マイクロRNA Let-7d を介した間葉系幹細胞エクソソームによる上皮間葉転換を介した特発性肺線維症の治療
24/06/02
Oxidative Inactivation of Cathepsin B in Idiopathic Pulmonary Fibrosis
M Tarte - 2024
… Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by repeated micro injuries to the respiratory epithelium that result in altered repair pathways. Oxidative stress has long been associated with IPF … Idiopathic …
- 特発性肺線維症におけるカテプシンBの酸化不活性化
C-type natriuretic peptide-Guanylyl cyclase B effects in Pulmonary Fibrosis
R Weyer, AL Friedrich, E Lessmann, L Krebes… - cGMP: Generators, Effectors …, 2024
… PF can be idiopathic (IPF) or secondary to severe inflammation. For instance, after SARS-… in cultured lung fibroblasts from patients with IPF. Additionally, to dissect possible protective … Notably, such inhibitory CNP actions were fully …
- 肺線維症におけるC型ナトリウム利尿ペプチド-グアニル酸シクラーゼBの効果
[HTML] Senegenin Attenuates Pulmonary Fibrosis by Inhibiting Oxidative-Stress-Induced Epithelial Cell Senescence through Activation of the Sirt1/Pgc-1α Signaling Pathway
Q Zeng, Y Luo, X Sang, M Liao, B Wen, Z Hu, M Sun… - Antioxidants, 2024
… epithelial cell senescence and in idiopathicpulmonary fibrosis, we postulate that the anti-pulmonary-fibrosis effect of senegenin may be … Owing to its antiaging effects, Sirt1 is used as a key target for the treatment of a variety of diseases …
- セネゲニンはSirt1/Pgc-1αシグナル伝達経路の活性化を介して酸化ストレス誘発性上皮細胞老化を阻害し、肺線維症を軽減する
[HTML] Ism1 deficiency in mice exacerbates bleomycin-induced pulmonary fibrosis with enhanced cellular senescence and delayed fibrosis resolution
M Shanmugasundaram, S Xu, Y Yang, JH Tee… - hLife, 2024
… Pulmonary fibrosis is a common pathological feature of many lung diseases including idiopathic pulmonary fibrosis (IPF), adult respiratory distress syndrome (ARDS), acute interstitial pneumonitis (AIP), and usual interstitial pneumonia (UIP) [1], [2], [3]. …
- マウスのIsm1欠損は、細胞老化を促進し、線維症の解消を遅らせ、ブレオマイシン誘発性肺線維症を悪化させる
24/06/01
Lung cancer and idiopathic pulmonary fibrosis: environmental exposures are the key
L Sesé, I Annesi-Maesano - European Respiratory Journal, 2024
… In idiopathic pulmonary fibrosis (IPF), the incidence of lung cancer is elevated, and its prognosis is worse compared to that in the general population [2]. The estimated incidence rate ratio (IRR) of developing lung cancer in … Male gender appears to pose …
- 肺がんと特発性肺線維症：環境曝露が鍵
[HTML] Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database
Y Kondoh, T Ito, K Saito, H Bao, W Sakamoto - Respiratory Investigation, 2024
… This retrospective cohort study estimated the incidence probability of progression to PPFs in patients with fibrosing ILDs other than idiopathicpulmonary fibrosis in a real-world Japanese setting. Management procedures and treatment patterns were …
- 進行性肺線維症（PPF）：保険請求データベースを用いた日本における発症率と治療率の推定
[HTML] Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
M Chianese, G Screm, F Salton, P Confalonieri… - Pharmaceuticals, 2024
… Pirfenidone and Nintedanib are specific drugs used against idiopathic pulmonary fibrosis(IPF) that showed efficacy in non-IPF fibrosing … : Nintedanib; Pirfenidone, interstitial lung disease, and idiopathic pulmonary fibrosis. The most widely …
- 肺線維症におけるピルフェニドンとニンテダニブ：光と影
[PDF] Proteomic and Single-Cell insights unveiling therapeutic potential of curcumin against IL-17A induced acute lung injury in C57BL/6 mice
MM Gouda, RDA Balaya, PK Modi, S Kadri… - 2024
… mechanism to regulate the ALI progression to idiopathic pulmonary brosis (IPF). C57BL/6 mice, … The integration of scRNA-seq data from 20 IPF and 10 control lung specimens emphasized … Human IPF single cell data integration con rmed the …
- プロテオームと単一細胞の知見により、C57BL/6マウスにおけるIL-17A誘発急性肺障害に対するクルクミンの治療効果が明らかに
Double lung transplantation in patients with recent history of malignancy.
T Demir, A Bharat, LILY Chung, W Woo, C Moloney… - 2024
e20614 Background: Recent history of malignancy has been considered as a contraindication for double lung transplantation (DLT) due to concerns for risk of cancer recurrence and worse outcomes. However, the relationship between the …
- 最近悪性腫瘍の病歴がある患者における両肺移植。
<>
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
